<DOC>
	<DOCNO>NCT00507689</DOCNO>
	<brief_summary>The objective 96-week study evaluate safety antiviral efficacy emtricitabine/tenofovir disoproxil fumarate ( FTC/TDF , coformulated ; Truvada® ) without hepatitis B immunoglobulin ( HBIg ) prevent recurrence chronic hepatitis B follow liver transplantation , participant chronically infect hepatitis B prior transplantation . Prior enrollment , participant require receive least 12 week HBIg therapy follow liver transplantation . Enrolled participant receive FTC/TDF plus HBIg initial 24-week pre-randomization treatment period . Participants complete pre-randomization period achieve sustained viral suppression randomize continue treatment FTC/TDF without HBIg additional 72 week ( randomized period ) . The antiviral efficacy treatment assess measure hepatitis B virus level blood ( HBV DNA ) . Safety tolerability monitor assess adverse event various laboratory parameter .</brief_summary>
	<brief_title>Truvada Versus Truvada Plus Hepatitis B Immunoglobulin ( HBIg ) Prevention Chronic Hepatitis B Recurrence Post Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Adult subject ( 1875 year age ) either hepatitis e antigen ( HBeAg ) positive HBeAg negative chronic HBV prior transplant Willing able provide write informed consent Subjects detectable antibody hepatitis B surface antigen perform local laboratory result within 30 day screen Subjects must stable may 2 follow laboratory parameter associate decompensated liver disease : conjugate bilirubin &gt; 1.5 x upper limit normal range ( ULN ) , prothrombin time &gt; 1.5 x ULN , platelets &lt; 60,000/mm^3 , serum albumin &lt; 3.0 g/dL Must least 12 week centerspecific prophylactic therapy include hepatitis B immunoglobulin ( HBIg ) posttransplant Calculated creatinine clearance ≥ 40 mL/min use CockcroftGault equation No significant evidence ongoing deterioration renal function Negative serum betahuman chorionic gonadotropin ( female childbearing potential ) Subjects HBV recurrence , ie , confirm HBV DNA ≥ 400 copies/mL , follow liver transplant Pregnant woman , woman breast feed believe may wish become pregnant course study Males females reproductive potential unwilling use effective method contraception study least 30 day date last dose study drug Evidence hepatocellular carcinoma ( HCC ) , eg , alphafetoprotein &gt; 50 ng/mL , standard care measure presence multifocal HCC time transplantation transplantation within 144 week screen Prior TDF FTC/TDF experience posttransplant &gt; 12 month treatment TDF FTC/TDF treatment pretransplant Coinfection hepatitis C virus ( serology ) , HIV , hepatitis D virus pretransplant screen Significant renal , cardiovascular , pulmonary , neurological disease Known hypersensitivity study drug , metabolite , formulation excipients Were likely receive systemic drug nephrotoxic potential , except immunosuppressive agent ( eg , cyclosporine , tacrolimus ) , course study History variceal bleed hepatic encephalopathy follow orthotopic liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Truvada</keyword>
	<keyword>HBIg</keyword>
	<keyword>Chronic Hepatitis B Recurrence</keyword>
	<keyword>Post Orthotopic Liver Transplant</keyword>
</DOC>